Matrix metalloproteinases and diabetic vascular complications

Angiology

Volumn 56, Issue 2, 2005, Pages 173-189

  Kadoglou, Nikolaos P ^a,d   Daskalopoulou, Stella S ^a,b   Perrea, Despina ^c   Liapis, Christos D ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c UNIVERSITY OF ATHENS   (Greece)

^d NONE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE 3; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 18; NEUTROPHIL COLLAGENASE; STROMELYSIN; STROMELYSIN 2; STROMELYSIN 3; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD CLOTTING DISORDER; DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; GLYCATION; HUMAN; HYPERGLYCEMIA; OXIDATIVE STRESS; PROTEIN EXPRESSION; REVIEW;

EID: 15544388564     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/000331970505600208     Document Type: Review

References (151)

1. King H, Aubert RE, Herman WH: Global burden of diabetes, 1995-2005. Prevalence, numerical estimates, projections. Diabetes Care 21:1414-1431, 1998.
2. Daskalopoulou SS, Mikhailidis DP, Elisaf M: Prevention and treatment of the metabolic syndrome. Angiology 2004; in press.
3. Grundy SM, Benjamin IJ, Burke GL, et al: Diabetes and cardiovascular disease. A statement for healthcare professionals from the American Heart Association. Circulation 100:1134-1146, 1999.
4. Imazu M, Sumii K, Yamamoto Y, et al: Influence of type 2 diabetes mellitus on cardiovascular disease mortality: Findings from the Hawaii-Los Angeles-Hiroshima study. Diabetes Res Clin Pract 57:61-69, 2002.
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001.
6. American Diabetes Association: Peripheral arterial disease in people with diabetes. Diabetes Care 26:3333-3341, 2003.
7. Brand FN, Abbot RD, Kannel WB: Diabetes, intermittent claudication and risk of cardiovascular events. The Framingham study. Diabetes 38:504-509, 1989.
8. Donnelly R, Davis K: Type 2 diabetes and atherosclerosis. Diabetes Obes Metab 2(suppl 1):S21-S30, 2000.
9. Nicholls AJ: The impact of atherosclerotic renovascular disease on diabetic renal failure. Diabet Med 19:889-894, 2002.
10. Alcazar JM, Marin R, Gomez-Campdera F, et al; Spanish Group of Ischaemic Nephrology (GEDENI): Clinical characteristics of ischaemic renal disease. Nephrol Dial Transplant 16(suppl 1):74-77, 2001.
11. Valabhji J, Robinson S, Poulter C, et al: Prevalence of renal artery stenosis in subjects with type 2 diabetes and coexistent hypertension. Diabetes Care 23:539-543, 2000.
12. Lederle FA, Johnson GR, Wilson SE, et al: The aneurysm detection and management study screening program: Validation cohort and final results. Aneurysm Detection and Management Veterans Affairs Cooperative Study Investigators. Arch Intern Med 160:1425-1430, 2000.
13. Shteinberg D, Halak M, Shapiro S, et al: Abdominal aortic aneurysm and aortic occlusive disease: A comparison of risk factors and inflammatory response. Eur J Vasc Endovasc Surg 20:462-465, 2000.
14. Blanchard JF, Armenian HK, Friesen PP: Risk factors for abdominal aortic aneurysm: Results of a case-control study. Am J Epidemiol 151:575-583, 2000.
15. Negase H, Woessner JF Jr: Matrix metalloproteinases. J Biol Chem 274:21491-21494, 1999.
16. Loftus IM, Naylor AR, Bell PRF, et al: Matrix metalloproteinases and atherosclerotic plaque instability. Br J Surg 89:680-694, 2002.
17. Visse R, Nagase H: Matrix metalloproteinases and tissue inhibitors of metalloproteinases: Structure, function and biochemistry. Circ Res 92:827-839, 2003.
18. Kadoglou NP, Liapis CD: Matrix metalloproteinases: Contribution to pathogenesis, diagnosis, surveillance and treatment of abdominal aortic aneurysms. Curr Med Res Opin 20:419-432, 2004.
19. Jones CB, Sane DC, Herrington DM: Matrix metalloproteinases: A review of their structure and role in acute coronary syndromes. Cardiovasc Res 59:812-823, 2003.
20. Galis Z, Muszynski M, Sukhova GK, et al: Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesions. Ann NY Acad Sci 748:501-507, 1995.
21. Uzui H, Harpf A, Liu M, et al: Increased expression of membrane type 3-matrix metalloproteinase in human atherosclerotic plaque. Role of activated macrophages and inflammatory cytokines. Circulation 106:3024-3030, 2002.
22. Galis ZS, Khatri J: Matrix metalloproteinases in vascular remodeling and atherogenesis. The good, the bad and the ugly. Circ Res 90:251-262, 2002.
23. Knox JB, Sukhova GK, Whittermore AD, et al: Evidence for altered balance between matrix metalloproteinases and their inhibitors in human aortic diseases. Circulation 95:205-212, 1997.
24. Death A, Fisher EJ, McGrath KCY, et al: High glucose alters matrix metalloproteinase expression in two key vascular cells: Potential impact on atherosclerosis in diabetes. Atherosclerosis 168:263-269, 2003.
25. Uemura S, Matsushita H, Li W, et al: Diabetes mellitus enhances vascular matrix metalloproteinase activity. Role of oxidative stress. Circ Res 88:1291-1298, 2001.
26. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 414:813-820, 2001.
27. Benbow U, Brinckerhoff C: The AP-1 site and MMP gene regulation: What is all the fuss about? Matrix Biol 15:519-526, 1997.
28. Wilmer W, Cosio F: DNA binding of activator protein-1 is increased in human mesangial cells cultured in high glucose concentrations. Kidney Int 53:1172-1181, 1998.
29. Pascal M, Knott R, Forrester J: Glucose mediated regulation of transforming growth factor beta in human retinal endothelial cells. Biochem Soc Trans 24:2285, 1996.
30. Jormso S, Ye S, Moritz J, et ai: Allele-specific regulation of matrix rnetalloproteinase-12 gene activity is associated with coronary artery luminal dimensions in diabetic patients with manifest coronary artery disease. Circ Res 86:998-1003, 2000.
31. Baugh MD, Gavrilovic J, Davies IR, et al: Monocyte matrix metalloproteinase production in type 2 diabetes and controls - a cross-sectional study. Cardiovasc Diabetol 2:3-7, 2003.
32. Portik-Dobos V, Anstadt MP, Hutchinson J, et al: Evidence for a matrix metalloproteinase induction/activation system in arterial vasculature and decreased synthesis and activity in diabetes. Diabetes 51:3063-3068, 2002.
33. Yan SF, Ramasamy R, Naka Y, et al: Glycation, inflammation and RAGE. A scaffold for the macrovascular complications of diabetes and beyond. Circ Res 93:1159-1169, 2003.
34. Virmani R, Kolodgie FD, Burke AP, et al: Lessons from sudden coronary death. A comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 20:1262-1275, 2000.
35. 2-dependent plaque instability. Circulation 104:921-927, 2001.
36. Ito H, Duxbury M, Benoit E, et al: Fibronectin-induced COX-2 mediates MMP-2 expression and invasiveness of rhabdomyosarcoma. Biochem Biophys Res Commun 318:594-600, 2004.
37. Cha HS, Ahn KS, Jeon CH, et al: Inhibitory effect of cyclo-oxygenase-2 inhibitor on the production of matrix metalloproteinases in rheumatoid fibroblast-like synoviocytes. Rheumatol Int 2003 Jul 26 [Epub ahead of print].
38. Kalogeropoulou K, Mortzos G, Migdalis I, et al: Carotid atherosclerosis in type 2 diabetes mellitus: Potential role of endothelin-1, lipoperoxides, and prostacyclin. Angiology 53:279-285, 2002.
39. Tsuruda T, Costello-Boerrigter LC, Burnett JC Jr: Matrix metalloproteinases: Pathways of induction by bioactive molecules. Heart Fail Rev 9:53-61, 2004.
40. Roy-Beaudry M, Martel-Pelletier J, Pelletier JP, et al: Endothelin 1 promotes osteoarthritic cartilage degradation via matrix rhetalloprotease 1 and matrix metalloprotease 13 induction. Arthritis Rheum 48:2855-2864, 2003.
41. Ergul A, Portik-Dobos V, Giulumian AD, et al: Stress upregulates arterial matrix metalloproteinase expression and activity via endothelin A receptor activation. Am J Physiol Heart Circ Physiol 285:H2225-2232, 2003.
42. Tostes RC, Touyz RM, He G, et al: Endothelin A receptor blockade decreases expression of growth factors and collagen and improves matrix metalloproteinase-2 activity in kidneys from stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol 39:892-900, 2002.
43. Jeremy JY, Mikhailidis DP, Dandona P: Simulating the diabetic environment modifies in vitro prostacyclin synthesis. Diabetes 32:217-221, 1983.
44. Cipollone F, Iezzi A, Fazia M, et al: The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques. Role of glycemic control. Circulation 108:1070-1077, 2003.
45. Jacob SS, Shastry P, Sudhakaran PR: Influence of non-enzymaticaily glycated collagen on monocyte-macrophage differentiation. Atherosclerosis 159:333-341, 2001.
46. Federici M, Menghini R, Mauriello A, et al: Insulin-dependent activation of endothelial nitric oxide synthase is impaired by O-linked glycosylation modification of signaling proteins in human coronary endothelial cells. Circulation 106:466-472, 2002.
47. Wagner AM, Martinez-Rubio A, Ordonez-Llanos A, et al: Diabetes mellitus and cardiovascular disease. Eur J Intern Med 13:15-30, 2002.
48. Maxwell PR, Timms PM, Chandrant S, et al: Peripheral blood level alterations of TIMP-1, MMP-2 and MMP-9 in patients with type 1 diabetes. Diabetes Med 18:777-780, 2001.
49. Dandona P, Aljada A, Mohanty P, et al: Insulin suppresses plasma concentration of vascular endothelial growth factor and matrix metalloproteinase-9. Diabetes Care 26:3310-3314, 2003.
50. Derosa G, Avanzini MA, Geroldi D, et al: Matrix metalloproteinase-2 may be a marker of microangiopathy in children and adolescents with type 1 diabetes mellitus. Diabetes Care 27:273-274, 2004.
51. Das A, McGuire PG, Eriqat C, et al: Human diabetic neovascular membranes contain high levels of urokinase and metalloproteinase enzymes. Invest Ophthalmol Vis Sci 40:809-813, 1999.
52. Saltzmann J, Limb GA, Khaw PT, et al: Matrix metalloproteinases and their natural inhibitors in fibrovascular membranes of proliferative retinopathy. Br J Ophthalmol 84:1091-1096, 2000.
53. McLennan SV, Death AK, Fisher EJ, et al: The role of the mesangial cell and its matrix in the pathogenesis of diabetic nephropathy. Cell Mol Biol 45:123-135, 1999.
54. Friedman EA: Advanced glycosylated end products and hyperglycemia in the pathogenesis of diabetic complications. Diabetes Care 22:B65-B71, 1999.
55. McLennan SV, Fisher EJ, Martell SKY, et al: Effects of glucose on matrix metalloproteinases and plasmin activity in mesangial cells: Possible role in diabetic nephropathy. Kidney Int 58(suppl 77):S81-S87 2000.
56. Phillips AO, Steadman R, Morrissey K, et al: Exposure of human renal proximal cells to glucose leads to accumulation type IV collagen and fibrinogen by decreased degradation. Kidney Int 52:973-984, 1997.
57. McLennan SV, Martell SKY, Yue DK: Effects of mesangium glycation on matrix metalloproteinase activities. Possible role in diabetic nephropathy. Diabetes 51:2612-2618, 2002.
58. McLennan SV, Fisher EJ, Yue DK, et al: High glucose concentration causes a decrease in mesangium degradation. A factor in the pathogenesis of diabetic nephropathy. Diabetes 43:1041-1045, 1994.
59. Kitamura M, Kitamura A, Mitarai T, et al: Gene expression of metalloproteinase and its inhibitor in mesangial cells exposed to high glucose. Biochem Biophys Res Commun 185:1055-1061, 1992.
60. Del Prete D, Anglani F, Forino M, et al: Down-regulation of glomerular matrix metalloproteinase-2 gene in human NIDDM. Diabetologia 40:1449-1454, 1997.
61. Fornoni A, Striker LJ, Zheng F, et al: Reversibility of glucose-induced changes in mesangial cell extracellular matrix depends on the genetic background. Diabetes 51:499-505, 2002.
62. Romanic AM, Burns-Kurtis CL, Zhaohui AO, et al: Upregulated expression of human membrane type-5 matrix metalloproteinase in kidneys from diabetic patients. Am J Physiol Renal Physiol 281:F309-F317, 2001.
63. Maeda S, Haeda M, Quo B, et al: Dinucleotide repeat polymorphism of matrix metalloproteinase-9 gene is associated with diabetic nephropathy. Kidney Int 60:1428-1434, 2001.
64. Ebihara I, Nakamura T, Shimada N, et al: Increased plasma metalloproteinase-9 concentrations precede development of microalbuminuria in non-insulin-dependent. Am J Kidney Dis 32:544-550, 1998.
65. Ishimura E, Nishizawa Y, Shoji S, et al: Serum type III, IV collagens and TIMP in patients with type II diabetes mellitus. Life Sci 58:1331-1337, 1996.
66. Ruilope LM, Segura J: Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: A review of the clinical trial evidence. Clin Ther 25:3044-3064, 2003.
67. Weinberg MS, Kaperonis N, Bakris GL: How high should an ACE inhibitor or angiotensin receptor blocker be dosed in patients with diabetic nephropathy? Curr Hypertens Rep 5:418-425, 2003.
68. Hayashi T, Sohmiya K, Ukimura A, et al: Angiotensin II receptor blockade prevents microangiopathy and preserves diastolic function in the diabetic rat heart. Heart 89:1236-1242, 2003.
69. Sakata Y, Yamamoto K, Mano T, et al: Activation of matrix metalloproteinases precedes left ventricular remodeling in hypertensive heart failure rats. Its inhibition as a primary effect of angiotensin-converting enzyme inhibitor. Circulation 109:2143-2149, 2004.
70. 2-dependent matrix metalloproteinase activity. Circulation 109:1482-1488, 2004.
71. Vu TH, Shipley JM, Bergers G, et al: MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 93:411-422, 1998.
72. Abaci A, Oguzhan A, Kahraman S, et al: Effect of diabetes mellitus on coronary collateral vessels. Circulation 99:2239-2242, 1999.
73. Rivard A, Silver M, Chen D, et al: Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. Am J Pathol 154:355-363, 1999.
74. Tamarat R, Silvestre JS, Hujiberts M, et al: Blockade of advanced glycation end-product formation restores ischemia-induced angiogenesis in diabetic mice. Proc Nat Acad Sci 100:8555-8560, 2003.
75. Taniyama Y, Morishita R, Hiraoka K, et al: Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat diabetic hind limb ischemia model. Molecular mechanisms of delayed angiogenesis in diabetes. Circulation 104:2344-2350, 2001.
76. McCarthy MJ, Loftus IM, Thompson MM, et al: Angiogenesis and the atherosclerotic carotid plaque: An association between symptomatology and plaque morphology. J Vasc Surg 30:261-268, 1999.
77. Wall SJ, Bevan D, Thomas DW, et al: Differential expression of matrix metalloproteinases during impaired wound healing of the diabetes mouse. J Invest Dermatol 119:91-98, 2002.
78. Vaalamo M, Leivo T, Saarialho-Kere U: Differential expression of tissue inhibitors of metalloproteinases (TIMP-1,-2,-3 and -4) in normal and aberrant wound healing. Hum Pathol 30:795-802, 1999.
79. Lobmann R, Ambrosch A, Schultz G, et al: Expression of matrix-metalloproteinases and their inhibitors in the wounds of diabetic and nondiabetic patients. Diabetologia 45:1011-1016, 2002.
80. Wall SJ, Sampson MJ, Levell N, et al: Elevated matrix metalloproteinase-2 and -3 production from human diabetic dermal fibroblasts. Br J Dermatol 149:13-16, 2003.
81. Goova MT, Li J, Kislinger T, et al: Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. Am J Pathol 159:513-525, 2001.
82. Witte MB, Kiyama T, Barbul A: Nitric oxide enhances experimental wound healing in diabetes. Br J Surg 89:1594-1601, 2002.
83. Verhofstad MHJ, Lomme RMLM, de Man BM, et al: Intestinal anastomoses from diabetic rats contain supranormal levels of gelatinase activity. Dis Colon Rectum 45:554-561, 2002.
84. Ryan ME, Ramamurthy NS, Sorsa T, et al: MMP-mediated events in diabetes. Ann NY Acad Sci 878:311-334, 1999.
85. Galis ZS, Sukhova GK, Lark MW, et al: Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 90:775-778, 1994.
86. Brown DL, Hibbs MS, Kearney M, et al: Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Circulation 91:2125-2131, 1995.
87. Loftus IM, Naylor AR, Goodall S, et al: Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption. Stroke 31:40-47, 2000.
88. Sukhova GK, Schonbeck U, Rabkin E, et al: Evidence for increased collagenolysis from interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation 99:2503-2509, 1999.
89. Herman MP, Sukhova GK, Libby P, et al: Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma. Circulation 104:1899-1904, 2001.
90. Halpert I, Sire UI, Roby JD, et al: Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. Proc Natl Acad Sci USA 93:9748-9753, 1996.
91. Hirashiki A, Yamada Y, Murase Y, et al: Association of gene polymorphisms with coronary artery disease in low- or high- risk subjects defined by conventional risk factors. J Am Coll Cardiol 42:1429-1437, 2003.
92. Libby P: Coronary artery injury and the biology of atherosclerosis: Inflammation, thrombosis and stabilization. Am J Cardiol 86:3J-9J, 2000.
93. Schonbeck U, Mach F, Sukhova GK, et al: Expression of stromelysin-3 in atherosclerotic lesions: Regulation via CD40-CD40 ligand signaling in vitro and in vivo. J Exp Med 189:843-853, 1999.
94. Rajavashisth TB, Xu X-P, Jovinge S, et al: Membrane type 1 matrix metalloproteinase expression in human atherosclerotic plaques: Evidence for activation by proinflammatory mediators. Circulation 99:3103-3109, 1999.
95. Uzui H, Harpf A, Liu M, et al: Increased expression of membrane type-3 matrix metalloproteinase in human atherosclerotic plaque. Role of activated macrophages and inflammatory cytokines. Circulation 106:3024-3030, 2002.
96. Moreno PR, Murcia AM, Palacios IF, et al: Coronary composition and macrophages infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation 102:2180-2184, 2000.
97. Haffner SM, Mykkanen L, Festa A, et al: Insulin resistant prediabetic subjects have more atherogenic risk factors than insulin sensitive prediabetic subjects: Implications for preventing coronary heart disease during the prediabetic state. Circulation 101:975-980, 2000.
98. Shah PK: Mechanisms of plaque vulnerability and rupture. J Am Coll Cardiol 41:15S-22S, 2003.
99. Bucciarelli LG, Wendt T, Qu W, et al: RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-Null mice. Circulation 106:2827-2835, 2002.
100. Nest RW, Rutter MK: Impact of atherosclerotic process in patients with diabetes. Acta Diabetol 39:S22-S28, 2002.
101. Kuzuya M, Asai T, Kanda S, et al: Glycation cross-links inhibit matrix metalloproteinase-2 activation in vascular smooth muscle cells cultured on collagen lattice. Diabetologia 44:433-436, 2001.
102. Vinik AI, Erbas T, Park TS, et al: Platelet dysfunction in type 2 diabetes. Diabetes Care 24:1476-1485, 2001.
103. Barradas MA, Gill DS, Fonseca VA, et al: Intraplatelet serotonin in patients with diabetes mellitus and peripheral vascular disease. Eur J Clin Invest 18:399-404, 1988.
104. Frohlich J, Steiner G: Dyslipidaemia and coagulation defects of insulin resistance. Int J Clin Pract Suppl 113:14-22, 2000.
105. Sambola A, Osende J, Hatcock J, et al: Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. Circulation 107:973-977, 2003.
106. Morishige K, Shimokawa H, Matsumoto Y, et al: Overexpression of matrix metalloproteinase-9 promotes intravascular thrombus formation in procine coronary arteries in vivo. Cardiovasc Res 97:572-585, 2003.
107. Sawicki G, Salas E, Murat J, et al: Release of gelatinase A during platelet activation mediates aggregation. Nature 386:616-619, 1997.
108. Sawicki G, Sanders EJ, Salas E, et al: Localization and translocation of MMP-2 during aggregation of human platelets. Thromb Haemost 80:836-839, 1998.
109. Galt SW, Lindermann S, Allen L, et al: Outside-in signals delivered by matrix metalloproteinase-1 regulate platelet function. Circ Res 90:1093-1099, 2002.
110. Kazes I, Elalamy I, Sraer JD, et al: Platelet release of trimolecular complex components MTl-MMP/ TIMP2/MMP2: Involvement in MMP2 activation and platelet aggregation. Blood 96:3064-3069, 2000.
111. Fernandez-Patron C, Martinez-Cuesta MA, Salas E, et al: Differential regulation of platelet aggregation by matrix metalloproteinases-9 and -2. Thromb Haemost 82:1730-1735, 1999.
112. Robless PA, Tegos TJ, Okonko D, et al: Platelet activation during carotid endarterectomy and the antiplatelet effect of Dextran 40. Platelets 13:231-239, 2002.
113. Robless PA, Okonko D, Lintott P, et al: Increased platelet aggregation and activation in peripheral arterial disease. Eur J Vasc Endovasc Surg 25:16-22, 2003.
114. Francis GA, Fayard E, Picard F, et al: Nuclear receptors and the control of metabolism. Annu Rev Physiol 65:261-311, 2003.
115. Francis GA, Annicotte JS, Auwerx J: PPAR agonists in the treatment of atherosclerosis. Curr Opin Pharmacol 3:186-191, 2003.
116. Shu H, Wong B, Zhou G, et al: Activation of PPARα or γ reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells. Biochem Biophys Res Commun 267:345-349, 2000.
117. Marx N, Schonbeck U, Lazar MA, et al: Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 83:1097-1103, 1998.
118. Haffner SM, Greenberg AS, Weston WM, et al: Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106:679-684, 2002.
119. Game B, Xu M, Lopes-Virella MF, et al: Regulation of MMP-1 expression in vascular endothelial cells by insulin-sensitizing thiazolidinediones. Atherosclerosis 169:235-243, 2003.
120. Marx N, Sukhova GK, Murphy C, et al: Macrophages in human atheroma contain PPARγ. Am J Pathol 153:17-23, 1998.
121. Hunt MJ, Tyagi SC: Peroxisome proliferators compete and ameliorate Hcy-mediated endocardial endothelial cell activation. Am J Physiol Cell Physiol 283:C1073-1079, 2002.
122. Sood HS, Hunt MJ, Tyagi SC: Peroxisome proliferator ameliorates endothelial dysfunction in a murine model of hyperhomocysteinemia. Am J Physiol Lung Cell Mol Physiol 284:L333-L341, 2003.
123. Rizos E, Bairaktari E, Ganotakis E, et al: Effect of ciprofibrate on lipoproteins, fibrinogen, renal function, and hepatic enzymes. J Cardiovasc Pharmacol Ther 7:219-226, 2002.
124. Tsimihodimos V, Kostoula A, Kakafika A, et al: Effect of fenofibrate on serum inflammatory markers in patients with high triglyceride values. J Cardiovasc Pharmacol Ther 9:27-33, 2004.
125. Balk EM, Lau J, Goudas LC, et al: Effects of statins on nonlipid serum markers associated with cardiovascular disease: A systematic review. Ann Intern Med 139:670-682, 2003.
126. Goudevenos JA, Bairaktari ET, Chatzidimou KG, et al: The effect of atorvastatin on serum lipids, lipoprotein(a) and plasma fibrinogen levels in primary dyslipidaemia-a pilot study involving serial sampling. Curr Med Res Opin 16:269-275, 2001.
127. Sager PT, Melani L, Lipka L, et al; Ezetimibe Study Group: Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. Am J Cardiol 92:1414-1418, 2003.
128. Ballantyne CM, Houri J, Notarbartolo A, et al; Ezetimibe Study Group: Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: A prospective, randomized, double-blind trial. Circulation 107:2409-2415, 2003.
129. Ridker PM, Rifai N, Clearfield M, et al; Air Force/ Texas Coronary Atherosclerosis Prevention Study Investigators: Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 344:1959-1965, 2001.
130. Hetzel M, Walcher D, Grub M, et al: Inhibition of MMP-9 expression by PPARgamma activators in human bronchial epithelial cells. Thorax 58:778-783, 2003.
131. Collins R, Armitage J, Parish S, et al: Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised, placebo-controlled trial. Lancet 361:2005-2016, 2003.
132. Papadakis JA, Milionis HJ, Press M, et al: Treating dyslipidaemia in non-insulin-dependent diabetes mellitus - a special reference to statins. J Diabetes Complications 15:211-226, 2001.
133. Athyros VG, Papageorgiou AA, Symeonidis AN, et al, for the GREACE study collaborative Group: Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus. Angiology 54:679-690, 2003.
134. Haffner SM, Lehto S, Ronnemaa T, et al: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229-234, 1998.
135. Bellosta S, Ferri N, Arnaboldi L, et al: Pleiotropic effects of statins in atherosclerosis and diabetes. Diabetes Care 23(suppl 2):B72-B78, 2000.
136. Luan Z, Chase AJ, Newby AC: Statins inhibit secretion of metalloproteinases-1,-2,-3, and -9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol 23:769-775, 2003.
137. Tsiara S, Elisaf M, Mikhailidis DP: Early vascular benefits of statin therapy. Curr Med Res Opin 19:540-556, 2003.
138. Daskalopoulou SS, Athyros VG, Elisaf M, et al: Uric acid levels and vascular disease. Curr Med Res Opin 20:951-954, 2004.
139. Athyros VG, Elisaf M, Papageorgiou AA, et al; GREACE Study Collaborative Group: Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: A subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis 43:589-599, 2004.
140. Elisaf M, Mikhailidis DP: Statins and renal function. Angiology 53:493-502, 2002.
141. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al: The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease: A subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. J Clin Pathol 2004; in press.
142. Liu R, Liote F, Rose DM, et al: Proline-rich tyrosine kinase 2 and Src kinase signaling transduce monosodium urate crystal-induced nitric oxide production and matrix metalloproteinase-3 expression in chondrocytes. Arthritis Rheum 50:247-258, 2004.
143. Hoieggen A, Alderman MH, Kjeldsen SE, et al; LIFE Study Group: The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 65:1041-1049, 2004.
144. Daskalopoulou SS, Athyros VG, Elisaf M, et al: The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004; in press.
145. Crisby M, Nordin-Fredriksson G, Shah PK, et al: Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: Implications for plaque stabilization. Circulation 103:926-933, 2001.
146. Siegel-Axel DI, Runge H, Seipel L, et al: Effects of cerivastatin on human arterial smooth muscle cell growth and extracellular matrix expression at varying glucose and low-density lipoprotein levels. J Cardiovasc Pharmacol 41:422-433, 2003.
147. Song Y, Li C, Cai L: Fluvastatin prevents nephropathy likely through suppression of connective tissue growth factor-mediated extracellular matrix accumulation. Exp Mol Pathol 76:66-75, 2004.
148. Furman C, Copin C, Kandoussi M, et al: Rosuvastatin reduces MMP-7 secretion by human monocyte-derived macrophages: Potential relevance to atherosclerotic plaque stability. Atherosclerosis 174:93-98, 2004.
149. Wierzbicki AS, Mikhailidis DP, Wray R, et al: Statin-fibrate combination therapy for hyperlipidaemia: A review. Curr Med Res Opin 19:155-168, 2003.
150. GISSI-Prevenzione Investigators: Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial. Lancet 354:447-455, 1999.
151. Chen H, Li D, Roberts GJ, et al: Eicosapentanoic acid inhibits hypoxia-reoxygenation-induced injury by attenuating upregulation of MMP-1 in adult rat myocytes. Cardiovasc Res 59:7-13, 2003.